Browse PTK6

Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Cell projection, ruffle. Membrane Note=Colocalizes with KHDRBS1, KHDRBS2 or KHDRBS3, within the nucleus. Nuclear localization in epithelial cells of normal prostate but cytoplasmic localization in cancer prostate.
Domain PF07714 Protein tyrosine kinase
PF00017 SH2 domain
PF00018 SH3 domain
Function

Non-receptor tyrosine-protein kinase implicated in the regulation of a variety of signaling pathways that control the differentiation and maintenance of normal epithelia, as well as tumor growth. Function seems to be context dependent and differ depending on cell type, as well as its intracellular localization. A number of potential nuclear and cytoplasmic substrates have been identified. These include the RNA-binding proteins: KHDRBS1/SAM68, KHDRBS2/SLM1, KHDRBS3/SLM2 and SFPQ/PSF; transcription factors: STAT3 and STAT5A/B and a variety of signaling molecules: ARHGAP35/p190RhoGAP, PXN/paxillin, BTK/ATK, STAP2/BKS. Associates also with a variety of proteins that are likely upstream of PTK6 in various signaling pathways, or for which PTK6 may play an adapter-like role. These proteins include ADAM15, EGFR, ERBB2, ERBB3 and IRS4. In normal or non-tumorigenic tissues, PTK6 promotes cellular differentiation and apoptosis. In tumors PTK6 contributes to cancer progression by sensitizing cells to mitogenic signals and enhancing proliferation, anchorage-independent survival and migration/invasion. Association with EGFR, ERBB2, ERBB3 may contribute to mammary tumor development and growth through enhancement of EGF-induced signaling via BTK/AKT and PI3 kinase. Contributes to migration and proliferation by contributing to EGF-mediated phosphorylation of ARHGAP35/p190RhoGAP, which promotes association with RASA1/p120RasGAP, inactivating RhoA while activating RAS. EGF stimulation resulted in phosphorylation of PNX/Paxillin by PTK6 and activation of RAC1 via CRK/CrKII, thereby promoting migration and invasion. PTK6 activates STAT3 and STAT5B to promote proliferation. Nuclear PTK6 may be important for regulating growth in normal epithelia, while cytoplasmic PTK6 might activate oncogenic signaling pathways.; FUNCTION: Isoform 2 inhibits PTK6 phosphorylation and PTK6 association with other tyrosine-phosphorylated proteins.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001933 negative regulation of protein phosphorylation
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0006469 negative regulation of protein kinase activity
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0010720 positive regulation of cell development
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0031346 positive regulation of cell projection organization
GO:0032526 response to retinoic acid
GO:0033673 negative regulation of kinase activity
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0038127 ERBB signaling pathway
GO:0038128 ERBB2 signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042326 negative regulation of phosphorylation
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042506 tyrosine phosphorylation of Stat5 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0045666 positive regulation of neuron differentiation
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045787 positive regulation of cell cycle
GO:0045926 negative regulation of growth
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046777 protein autophosphorylation
GO:0048565 digestive tract development
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050732 negative regulation of peptidyl-tyrosine phosphorylation
GO:0050769 positive regulation of neurogenesis
GO:0051348 negative regulation of transferase activity
GO:0051962 positive regulation of nervous system development
GO:0055123 digestive system development
GO:0060575 intestinal epithelial cell differentiation
GO:0061097 regulation of protein tyrosine kinase activity
GO:0061099 negative regulation of protein tyrosine kinase activity
GO:0071229 cellular response to acid chemical
GO:0071300 cellular response to retinoic acid
GO:0071396 cellular response to lipid
GO:0097696 STAT cascade
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
Cellular Component GO:0001726 ruffle
GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0031252 cell leading edge
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-8847993: ERBB2 Activates PTK6 Signaling
R-HSA-69206: G1/S Transition
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-8849474: PTK6 Activates STAT3
R-HSA-8849472: PTK6 Down-Regulation
R-HSA-8849473: PTK6 Expression
R-HSA-8849470: PTK6 Regulates Cell Cycle
R-HSA-8849468: PTK6 Regulates Proteins Involved in RNA Processing
R-HSA-8849471: PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
R-HSA-8849469: PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
R-HSA-8857538: PTK6 promotes HIF1A stabilization
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-162582: Signal Transduction
R-HSA-1227986: Signaling by ERBB2
R-HSA-8848021: Signaling by PTK6
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTK6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTK6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTK6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.280.61
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7190.413
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.020.168
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2060.739
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2370.908
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1510.944
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8010.215
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1880.211
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4490.653
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-1.3570.0369
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-1.8720.0265
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2560.347
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTK6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTK6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTK6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTK6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTK6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTK6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTK6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTK6
Nameprotein tyrosine kinase 6
Aliases BRK; PTK6 protein tyrosine kinase 6; breast tumor kinase; protein-tyrosine kinase BRK; tyrosine-protein kina ......
Chromosomal Location20q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTK6 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting PTK6.
ID Name Drug Type Targets #Targets
DB05294VandetanibSmall MoleculeEGFR, PTK6, RET, TEK, VEGFA5